Grafeel pfs

Grafeel is a medication used to treat certain types of cancer, including acute myeloid leukemia, breast cancer, and non-Hodgkin’s lymphoma. It is an injectable medication that works by stimulating the production of white blood cells in the body.

Composition:

Grafeel contains Filgrastim, a medication that is a granulocyte colony-stimulating factor (G-CSF).

Indications:

Grafeel is indicated for the treatment of:

1. Neutropenia (reduced white blood cell count) caused by chemotherapy
2. Acute myeloid leukemia (AML)
3. Breast cancer (in combination with chemotherapy)
4. Non-Hodgkin’s lymphoma (in combination with chemotherapy)

Mechanism of Action:

Filgrastim works by:

1. Stimulating the production of granulocytes (a type of white blood cell) in the bone marrow
2. Increasing the number of circulating white blood cells in the body
3. Enhancing the function of white blood cells

Dosage and Administration:

The recommended dosage of Grafeel is:

• 300mcg/m2 injected subcutaneously or intravenously once daily
• The dose should be adjusted based on the patient’s response to treatment and tolerability

Side Effects:

Common side effects of Grafeel include:

1. Injection site reactions (pain, swelling, redness)
2. Bone pain
3. Headache
4. Fatigue
5. Nausea and vomiting
6. Diarrhea
7. Allergic reactions

Serious side effects can include:

1. Allergic reactions (anaphylaxis)
2. Bone marrow toxicity (decreased bone marrow function)
3. Leukocytosis (increased white blood cell count)
4. Thrombocytopenia (decreased platelet count)
5. Hypersensitivity reactions

Contraindications:

Grafeel is contraindicated in patients with:

1. Hypersensitivity to Filgrastim or other G-CSF medications
2. Severe allergic reactions to other medications
3. Severe neutropenia (less than 500 neutrophils/μL)

Precautions:

1. Patients with a history of allergic reactions to other medications should be closely monitored while receiving Grafeel.
2. Patients with a history of bone marrow disorders should be closely monitored while receiving Grafeel.
3. Patients with a history of liver or kidney disease should be closely monitored while receiving Grafeel.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of injection site reactions or allergic reactions.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.